Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q1 2024 Earnings Conference
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q1 2024 Earnings Conference
The following is a summary of the Theralase Technologies Inc. (TLTFF) Q1 2024 Earnings Call Transcript:
以下是Theralase Technologies Inc. (TLTFF) 2024年第一季度業績會交流摘要:
Financial Performance:
金融業績：
Theralase's Q1 2024 total revenue decreased by 15% year-over-year.
Gross margin for Q1 decreased to 35% from 45% year-over-year, attributed to lower revenue volume and increased material costs.
Net loss improved by 10% year-over-year to $1,266,711.
Theralase2024年第一季度總營業收入同比下降15%。
第一季度毛利率同比從45%下降至35%，歸因於成交量下降和材料成本上升。
淨虧損同比改善了10%至$1,266,711。
Business Progress:
業務進展：
Theralase completed two non-brokered private placements raising a total of $2 million.
The company is actively seeking to secure funding through a potential $100 million base shelf prospectus to support their Phase II bladder cancer clinical study and expand into brain and lung cancer clinical studies.
Theralase完成了兩項非經紀人私人配售，共籌集了200萬美元。
公司正在積極通過潛在的1億美元的基礎招股書尋求資金支持其Ⅱ期膀胱癌臨床研究並擴大到腦部和肺部癌症臨床研究。
Opportunities:
機會：
Advanced Phase II bladder cancer clinical study with strong preliminary results showing high response rates.
Potential to expand into additional cancer treatments including brain and lung cancer, and development of a vaccine for avian influenza.
廣受歡迎的Ⅱ期膀胱癌臨床研究顯示出很高的反應率。
有潛力擴展到其他癌症治療，包括腦癌、肺癌，並開發一種禽流感疫苗。
Risks:
風險：
Risk of low patient enrollment impacting the completion timeline for the Phase II bladder cancer study.
Financial challenges in maintaining sufficient funding to support ongoing research and development.
存在低患者招募率的風險，影響Ⅱ期膀胱癌研究的完成時間表。
在保持足夠的資金支持進行持續的研究和開發方面存在財務上的挑戰。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。